Understanding and treating T cell issues in CHARGE syndrome using specialized cells

Modeling and treating T cell immunodeficiency in CHARGE syndrome by ESC- and iPSC-derived thymic epithelial cells

NIH-funded research University of Connecticut Storrs · NIH-11009900

This study is looking at how special cells made from stem cells can help people with CHARGE syndrome develop healthier immune systems by improving the function of their thymus, which is important for making T cells.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Connecticut Storrs NIH-funded
Lab location1 site (Storrs-Mansfield, United States)
Project IDNIH-11009900 on NIH RePORTER

What this research studies

This research focuses on CHARGE syndrome, a condition that can lead to significant T cell immunodeficiency due to problems with thymus development. The study aims to investigate how thymic epithelial cells, derived from embryonic stem cells, can be used to restore normal thymic function and support T cell development in affected individuals. By using advanced cell differentiation techniques, researchers hope to create a supportive environment for T cell maturation, which is crucial for a healthy immune response. Patients with CHARGE syndrome may benefit from this innovative approach to improve their immune function.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with CHARGE syndrome who experience T cell immunodeficiency.

Not a fit: Patients without CHARGE syndrome or those whose immunodeficiency is not related to thymic development may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could significantly enhance immune function in patients with CHARGE syndrome, potentially reducing their susceptibility to infections.

How similar studies have performed: While this approach is innovative, similar strategies using stem cell-derived thymic epithelial cells have shown promise in preliminary studies, indicating potential for success.

Where this research is happening

Storrs-Mansfield, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions 22q11 Chromosomal Microdeletion Syndrome22q11 Deletion Syndrome22q11.2 deletion syndromeAutosomal dominant Opitz G/BBB syndrome
Last reviewed 2026-06-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.